Humanized, glycoengineered type II anti-CD20 monoclonal antibody that depletes CD20+ pre-B and mature B cells with enhanced ADCC and direct cell death and reduced complement dependence, aiming to lower PR3-ANCA production and small-vessel inflammation.
Humanized, glycoengineered type II anti-CD20 IgG1 that binds CD20 on pre-B and mature B cells; Fc glycoengineering increases affinity for Fc gamma RIIIa, enhancing ADCC and phagocytosis, and induces direct, caspase-independent cell death with reduced complement dependence, leading to B-cell depletion and reduced PR3-ANCA production.
YES
DIRECT
Obinutuzumab binds CD20 on B cells and kills them via enhanced ADCC (FcγRIIIa-mediated NK cell cytotoxicity), antibody-dependent phagocytosis by myeloid cells, and induction of direct, caspase-independent cell death; complement involvement is minimal.
Humanized, glycoengineered type II anti-CD20 monoclonal antibody that depletes CD20+ pre-B and mature B cells with enhanced ADCC and direct cell death and reduced complement dependence, aiming to lower PR3-ANCA production and small-vessel inflammation.
Humanized, glycoengineered type II anti-CD20 IgG1 that binds CD20 on pre-B and mature B cells; Fc glycoengineering increases affinity for Fc gamma RIIIa, enhancing ADCC and phagocytosis, and induces direct, caspase-independent cell death with reduced complement dependence, leading to B-cell depletion and reduced PR3-ANCA production.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its afucosylated Fc engages FcγRIIIa (CD16a) on NK/myeloid cells to trigger ADCC and phagocytosis of CD20+ B cells. CD16a-expressing cells act as effectors and are not directly killed by the drug.
Chimeric type I anti-CD20 monoclonal antibody that depletes CD20+ pre-B and mature B cells primarily via complement-dependent cytotoxicity and ADCC to reduce PR3-ANCA levels and downstream neutrophil-driven inflammation.
Chimeric type I anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, reducing PR3-ANCA production and downstream neutrophil-driven inflammation.
YES
DIRECT
Anti-CD20 antibody binding triggers complement-dependent cytotoxicity and Fc-mediated ADCC/ADCP by immune effectors (e.g., NK cells, macrophages), depleting CD20+ B cells.
Radiolabeled anti-PSMA monoclonal antibody that binds PSMA on prostate cancer cells and delivers lutetium-177 beta radiation to induce DNA damage and tumor cell death.
A radiolabeled anti-PSMA monoclonal antibody that binds PSMA on prostate cancer cells and delivers lutetium-177 beta radiation, causing localized DNA damage (including double-strand breaks) and tumor cell death.
YES
DIRECT
The anti-PSMA antibody delivers 177Lu beta radiation to PSMA-expressing cells, causing localized ionizing radiation–induced DNA damage (including double-strand breaks) leading to cell death (with some crossfire to nearby cells).
Radiolabeled anti-PSMA monoclonal antibody variant used for biodistribution and dosimetry assessment, delivering lutetium-177 beta radiation to PSMA-expressing tumor cells.
Radiolabeled anti-PSMA monoclonal antibody (TLX591 variant, DOTA-chelated to lutetium-177) that binds PSMA on prostate cancer cells and delivers 177Lu beta radiation at the tumor site, causing DNA damage (double-strand breaks) and cell death, with cross-fire effects to nearby PSMA-expressing cells.
YES
DIRECT
Radiolabeled anti-PSMA antibody binds PSMA and delivers 177Lu beta radiation to the target cell, causing DNA double-strand breaks and cell death (with cross-fire to nearby cells).